Coronary/Structural Heart

Anthos Therapeutics’ novel Factor XI inhibitor abelacimab significantly outperforms standard of care enoxaparin in prospective Phase 2 efficacy research published today in the New England Journal of Medicine

Abelacimab achieved a ~80% reduction in venous thromboembolism versus a standard of care comparator in gold standard proof-of-concept efficacy study, indicating its potential in a range of thromboembolic disorders CAMBRIDGE, Mass., July 19, 2021 /PRNewswire/ — Anthos Therapeutics, a clinical-stage biopharma company developing innovative therapies for cardiovascular and metabolic diseases, today announced final […]

Cytokinetics Announces Positive Topline Results of Redwood-HCM

Phase 2 Clinical Trial of CK-274 Demonstrated Consistent and Clinically Meaningful Reductions in Left Ventricular Outflow Tract Gradients Within Two Weeks in Patients with Obstructive Hypertrophic Cardiomyopathy No Treatment Interruptions or Discontinuations Due to Reduction in Left Ventricular Ejection Fraction Phase 3 Registrational Trial of CK-274 Expected to Start Before […]

Imbria Pharmaceuticals Announces Initiation of Enrollment in IMPROVE-HCM, a Phase 2 Study Investigating the Safety, Tolerability, and Efficacy of IMB-1018972 (IMB-101) in Patients With Non-Obstructive Hypertrophic Cardiomyopathy

BOSTON–(BUSINESS WIRE)–Imbria Pharmaceuticals, a clinical stage biopharmaceutical company developing novel therapies designed to enhance cellular energetics for the treatment of major forms of heart disease and specific inborn errors of metabolism, today announced that the Hypertrophic Cardiomyopathy Center at Boston-based Tufts Medical Center has randomized the first patient in the […]

CORCYM Announces the First Patient Enrolled in MANTRA Study

MANTRA is the new CORCYM post-market clinical follow-up study in a real-world setting LONDON–(BUSINESS WIRE)–CORCYM, the new, independent, medical device company dedicated to providing patients and cardiac surgeons with the best solutions to fight structural heart disease, announces today the enrollment of the first patient in the MANTRA study. MANTRA (Mitral, Aortic […]

Elucid Presents Data Demonstrating Its AI Software Can Uniquely Quantify Key Drivers of Heart Attack and Stroke from Computed Tomography

Elucid Founder, Andrew Buckler, To Present Findings at the SCCT Annual Scientific Meeting BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software for physicians to optimize the treatment of patients with known or suspected vascular disease, announced today that its founder Andrew Buckler will present findings from two separate studies […]

CARMAT Announces the First Human Implant of Its Total Artificial Heart in the United States

The implant was performed at Duke University Hospital, one of the largest U.S. cardiology centers PARIS–(BUSINESS WIRE)–Regulatory News: CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage […]

Viz.ai and Avicenna.AI Partner to Launch World-class AI-Driven Intelligent Care Coordination for Pulmonary Embolism and Aortic Disease

SAN FRANCISCO & PARIS–(BUSINESS WIRE)–Viz.ai, the world leader in AI-driven intelligent care coordination, has partnered with Avicenna.AI, a global leader in artificial intelligence solutions, to enable intelligent care coordination and improve patient triage of patients suffering from pulmonary embolism (PE) and aortic disease. The collaboration will pave the way for faster […]

First Five Patients Successfully Treated with atHeart Medical’s Novel reSept™ Atrial Septal Defect Occluder in U.S. IDE Pivotal Trial

The first occluder with a metal-free, bioresorbable frame for the treatment of patients with clinically significant, isolated ASDs BAAR, Switzerland and MOUNTAIN VIEW, Calif., July 14, 2021 /PRNewswire/ — atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today announced the successful treatment of […]

scPharmaceuticals Inc. Announces Positive Top-Line Results from FREEDOM-HF Study

Reduced average 30-day heart failure related costs by $17,753 (p<0.0001) per study subject in FUROSCIX® arm compared to historically matched comparators Study halted early due to highly statistically significant reduction in 30-day heart failure-related costs observed during the prespecified interim analysis Company to host conference call and live webcast tomorrow, July […]

East End Medical Announces FDA Clearance Of Its SafeCross™ Transseptal RF Puncture And Steerable Balloon Introducer System

Novel 3-in-1 system provides predictable left atrium access to support transseptal interventions MIAMI, July 13, 2021 /PRNewswire/ — East End Medical, a private medical device company committed to improving catheter-based cardiac procedures, today announced it received U.S. Food and Drug Administration (FDA) clearance for the company’s SafeCross™ Transseptal Radiofrequency (RF) Puncture & Steerable Balloon […]